Deecke L, Zeiler K
Neurologische Universitätsklinik, Wien.
Wien Klin Wochenschr. 1993;105(17):485-7.
Acetylsalicylic acid (ASA) as secondary prophylaxis after ischaemic cerebrovascular events is well established and its efficacy unquestioned since over 15 years. According to the results of two European studies a dose of 100 mg per day is sufficient to reduce the incidence of further stroke, myocardial infarction, and death due to cardiovascular causes. This satisfactory response to low-dose ASA applies to patients with transient ischaemic attacks, reversible ischaemic events, and minor strokes. In cases with severe cardiac disease, however, a high dosage of ASA or anticoagulation therapy may be necessary to prevent further vascular events.
阿司匹林(ASA)作为缺血性脑血管事件后的二级预防药物已被广泛应用超过15年,其疗效毋庸置疑。根据两项欧洲研究的结果,每天100毫克的剂量足以降低因心血管原因导致的再次中风、心肌梗死和死亡的发生率。低剂量ASA对短暂性脑缺血发作、可逆性缺血事件和轻度中风患者有令人满意的疗效。然而,对于患有严重心脏病的患者,可能需要高剂量的ASA或抗凝治疗以预防进一步的血管事件。